On November 11, Caris Life Sciences, Inc. rose 4.46% in Regular Trading, trading at $25.27 per share, with turnover of $4.2085 million.
The move followed a rebound after post-earnings selling, alongside the company’s announcement that it enrolled the first patients in a genome sequencing study for myeloid cancers.
Caris Life Sciences, Inc. previously reported Q3 EPS of $0.05, above consensus expectations of $0.03 to $0.04, while revenue rose to $275.4 million from $216.8 million a year earlier and exceeded the roughly $255.4 million forecast. The company also raised full-year revenue guidance to $1.04 billion to $1.05 billion from $1.03 billion to $1.04 billion. On November 11, it additionally disclosed first-patient enrollment in a ChromoSeq study expected to enroll about 300 adults across multiple U.S. institutions, adding a fresh company-specific update as shares bounced after earlier pressure.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments